DLA Piper represented Seattle-based Stratos Genomics, an early-stage sequencing technology company, in its acquisition by biotechnology company Roche.
Roche plans to use Stratos’ Sequencing by Expansion (SBX) chemistry to advance the development of its nanopore sequencer, with the aim of providing an affordable, fast and flexible result for multiple targeted clinical applications, as well as whole exome and whole genome sequencing.
“Our extensive sector knowledge and M&A experience in the life sciences, pharmaceutical and biotechnology fields were critical in our representation of Stratos Genomics in this important transaction with Roche,” said John Steel, DLA Piper partner and lead counsel. “We were pleased to assist with this transaction and look forward to seeing the beneficial impact of these combined technologies.”
Along with Steel, the DLA Piper team representing Stratos Genomics included associate Kerra Melvin (both of Seattle).
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex cross-border transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for ten consecutive years, according to Mergermarket.
DLA Piper advises on all aspects of the life sciences sector, combining subject matter experience with considerable knowledge of the scientific, medical, regulatory, commercial and enforcement environments facing biopharmaceutical, medical device, research and diagnostics clients. Recognizing that clients’ needs vary, the firm rapidly organizes and customizes client service teams, whether for a large pharmaceutical company, a mid-sized medical device client or a development-stage biotech company.
Source: BioSpace
